anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, veterinary science. SUBSTANCE: antiviral preparation for injections has a mixture of an aqueous solution of organic substance with saline solution. Preparation has formaldehyde as organic substance and sodium chloride an aqueous solution as saline solution at the following ratio of components, wt.-%: formaldehyde an aqueous solution 0.03-0.3 and sodium chloride an aqueous solution at concentration 0.85-0.95% - the rest. Invention can be used for treatment of viral diseases and diseases caused by disorders of hormonal and nervous systems. EFFECT: broadened arsenal of antiviral drugs. 2 cl, 8 ex
Conversation Training Therapy will be administered one time per week for 1 hour. Ambulatory Voice Monitoring with Biofeedback will be administered during the second therapy session and for 5 days between the second and third therapy sessions.
The invention provides a multi-cell immune preparation for treating tumors and a preparation method of multi-cell immune preparation and relates to an immune preparation and a preparation method thereof. According to the multi-cell immune preparation and the preparation method, the problems that the treatment of existing immune cell preparations to the tumors is relatively limited, and the infusion safety cannot be guaranteed are solved. The multi-cell immune preparation comprises immune cells, human serum albumin and compound electrolyte. The preparation method comprises the following steps: (1) preparation of autologous plasma; (2) separation of peripheral blood mononuclear cells PBMC; (3) preparation of DC; (4) preparation of CIK; (5) preparation of NK cells; (6) preparation of CD3AK; (7) preparation of gamma delta T; (8) preparation of the multi-cell immune preparation. The multi-cell immune preparation has broad spectrum activity to the treatment of the tumors, the immune cells are derived from the body of a patient, and exogenous substances such as fetal calf serum, trophoblast cells and the like are not introduced, so that the infusion safety is guaranteed. The multi-cell immune preparation is applied to the field of tumor treatment.
Capecitabine is readily absorbed from the gastrointestinal tract. In the liver, a 60 kDa carboxylesterase hydrolyzes much of the compound to 5'-deoxy-5-fluorocytidine (5'-DFCR). Cytidine deaminase, an enzyme found in most tissues, including tumors, subsequently converts 5'-DFCR to 5'-deoxy-5-fluorouridine (5'-DFUR). The enzyme, thymidine phosphorylase (dThdPase), then hydrolyzes 5'-DFUR to the active drug 5-FU. Many tissues throughout the body express thymidine phosphorylase. Some human carcinomas express this enzyme in higher concentrations than surrounding normal tissues.

Metabolic Pathway of capecitabine to 5-FU
Participants received GWP42003-P 20 mg/kg/day administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
Face-to-face pilates training, which lasts for a total of 8 weeks, 3 days a week for 1 hour, will be carried out by Australian Pilates and Physiotherapy Institute certified and experienced Ph.D. Physiotherapist Halil Ibrahim Bulguroglu. Face-to-face pilates training will be held at Ankara Medipol University. To make the exercises more effective, the individuals in both pilates exercise groups will be divided into six small groups of 3 or 4 people. In this study, the program will be 15 minutes of warm-up, 30 minutes of pilates exercises, 15 minutes of cool-down and stretching exercises, and the exercises will be performed as 10 repetitions. The same exercises will be applied in online pilates and face-to-face pilates trainings.
Under sterile conditions,the posterior rectus sheath will be identified by ultrasound, and an insulated 22 gauge 50 mm needle inserted till the tip is seen to be directly between the rectus abdominis muscle and the posterior rectus sheath. Bupivacaine 0.25% (0.2 ml/kg with maximum 5 ml in each side) will be injected observing the spread on the ultrasound image.
The colon OFDI catheter will be used in conjunction with a sigmoidoscope. If a sigmoid polyp is identified, the colonoscope will be removed and a sigmoidoscope inserted. The colon OFDI catheter will be advanced through the sigmoidoscope accessory port and positioned adjacent to the colon wall. Imaging will be performed with the OFDI system across the polyp's surface and the base/stalk if pedunculated. The investigators anticipate that on average the investigators will utilize 4 helical scans per polyp. Each of the scans will take less than 30 seconds.
PURPOSE: A method for manufacturing a nanocapsule is provided to enhance resistance with respect to pH change. CONSTITUTION: A nanocapsule contains protein drugs which is encapsulated in PEG-POSS(polyethylene glycol polyhedral oligometric silsesquioxanes) through self-assembling. The protein drug is insulin. The average diameter of the nanocapsule is 20-80 nm. A pharmaceutical product or food contains the nanocapsules. A method for manufacturing the nanocapsule comprises: a step of preparing the PEG-POSS(S1); a step of dissolving PEG-POSS in a solvent to prepare a PEG-POSS solution(S2); and a step of adding hydrophobic drugs into the PEG-POSS solution.
QTc interval prolongation, which may lead to an increased risk for ventricular tachyarrhythmia (e.g., torsades de pointes) or sudden death, occurred in patients treated with ZYKADIA [see Adverse Reactions (6.1)]. Across clinical studies, 6% of 919 patients with at least one post-baseline electrocardiogram (ECG) assessment had an increase from baseline of QTc > 60 msec. Approximately 1.3% of patients taking ZYKADIA 750 mg under fasted conditions were found to have a QTc > 500 msec. ZYKADIA causes concentration-dependent increases in the QTc interval [see Clinical Pharmacology (12.2)]. Across clinical studies, 0.2% of patients discontinued ZYKADIA due to QTc prolongation. 

When possible, avoid use of ZYKADIA in patients with congenital long QT syndrome. Conduct periodic monitoring with ECGs and electrolytes in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or those who are taking medications that are known to prolong the QTc interval. Based on the severity of the adverse reaction, withhold ZYKADIA, with resumption at a reduced dose, or permanently discontinue ZYKADIA [see Dosage and Administration (2.3)].
The inventors examined APOM mRNA level and secretion in AT from patients in 6 independent clinical trials and in vitro in hMADS adipocytes. APOM expression and secretion were measured during dietary interventions. The inventors show that APOM is expressed in human subcutaneous and visceral AT and is released into circulation from AT. APOM expression in AT is lower in obese compared to lean individuals and reduced in subjects with metabolic syndrome and type 2 diabetes. Regardless of fat depot, there is a positive relationship between AT APOM expression and systemic insulin sensitivity. Finally, the inventors show that overexpression of APOM in the AT reduces AT inflammation and improves local insulin sensitivity during high fat diet induced obesity. Thus, the present invention relates to the present invention relates to the use of the apolipoprotein M for the treatment and diagnosis of insulin resistance.
Diabetic retinopathy (DR) is the most common retinal disorder, developed in 35% of patients with diabetes mellitus. Lower serum levels of 25-hydroxyvitamin D are associated with the increased risk of developing DR. High doses of the active form of vitamin D (VD), on the contrary, for a long period of time may lead to hypercalcemia and an imbalance in the regulation of bone metabolism. Herein, we studied the efficacy of dextran-gated carboxyphenylboronic acid (CPBA)-functionalized mesoporous silica nanoparticles (MSNs) for glucose-sensitive delivery of 1,25-dihydroxyvitamin D3 to modulate cellular oxidative stress and inflammation for managing DR. The physical adsorption technique was employed to load VD onto nanoparticles (263.63 μg/mg (w/w)). In the presence of glucose, the dextran molecules detach from pores, allowing VD to release since glucose has 1,2-cis diol groups which have very high affinity to CPBA. Approximately 75% of VD was released upon exposure to 25 mM glucose at a time point of 10 h, demonstrating glucose-responsive delivery. Furthermore, MSN-CPBA was able to deliver VD in a glucose-dependent manner and improve the bioavailability of VD. In high-glucose-supplemented human retinal cells, MSN-CPBA increased the bioavailability of VD and reduced cellular oxidative stress and inflammation. The results suggested that the VD-loaded nanocarrier exerted remarkable therapeutic capacity in reducing the risk of developing DR. By using MSN-CPBA as a delivery platform with dextran gating, the research proposes an effective treatment approach for improving the bioavailability and effectiveness of a hydrophobic molecule in the treatment of DR.
Human Normal Immunoglobulin for Subcutaneous Administration (IgPro20) is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
Participants will receive 0.75 milligrams (mg) of JNJ-55375515 (starting dose) or Placebo on Day 1. Dose of the study medication will be escalated sequentially up to a maximum of 200 mg.
Start of treatment within 6 weeks of inclusion in the study. 100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
PROBLEM TO BE SOLVED: To obtain the subject new compound derivative useful as a medicine, etc., e.g. anticancer agent, immunosuppressant or anti-HIV agent by reacting a specific protected disaccharide derivative with a specific alcohol derivative containing an unsaturated long-chain aliphatic hydrocarbon group and deprotecting the reaction product. SOLUTION: This new β-digalactosylceramide derivative is represented by formula I (R<2> is pentadecanyl group, heptadecanyl group or 8heptadesenyl group) and useful as a medicine, etc., effective for indications, e.g. anticancer agents (anticancer agents or metastasis suppressants), immunosuppre'ssants (for organ transplantation, etc.), anti-HIV agents, antitoxin action and Gauche disease. The compound is obtained by reacting a protected disaccharide active substance represented by formula H (R<1> is a protecting group of hydroxyl group; X is a halogen) with an alcohol derivative represented by the formula ROH [R is a group of formula III (R<3> is same kind as R<2> ) to afford a protected β- digalactosylceramide derivative represented by formula IV and then, deprotecting the derivative.
The effectiveness of polypropylene (PP) mesh is often compromised by severe inflammation. Engineering anti-inflammatory coatings has significant implications for PP mesh to repair unwanted hernias. Here, we presented a facile strategy to develop an anti-fouling coating consisting of zwitterionic poly(carboxybetaine methacrylate) (PCBMA), which could prohibit protein adsorption to endow PP mesh with anti-inflammatory efficacy. The incorporation of PCBMA coating had little impact on the raw features of PP mesh. While the modified mesh PCBMA-PP possessed noticeable hydrophilicity increase and surface charge reduction. The excellent lubricity and surface stability enabled PCBMA-PP to exhibit superior anti-fouling capacity, thus efficiently inhibiting the adsorption of proteins. In vivo experiments showed that incorporating the PCBMA layer could provide PP meshes with outstanding anti-inflammatory effects and tissue compatibility for repairing hernias.
PROBLEM TO BE SOLVED: To improve contrast of a magnetic resonance image in a short image- catching time without lowering an S/N and a spatial resolution, by using as contrast media a paramagnetic substance showing an electron spin resonance transition of a specific magnetic flux density width. SOLUTION: A paramagnetic substance showing an electron spin resonance transition of a line width of 10<-4> Tesla (T) or smaller is used to form contrast media for forming of magnetic resonance images with an electron spin resonance excited. Particularly, the paramagnetic substance is a physiologically permissible nitroxide stabilization free radical having a line width of 10μT or smaller. The paramagnetic substance is introduced into a body to be tested, and the body to be tested is exposed to a sequence of pulses of a first radiation of a set frequency, by which a nuclear spin transition of a selected nucleus in the body is excited. A free induced attenuation signal from the body in the sequence is detected.  Further, the body is exposed to a second radiation of a set frequency, thereby to excite an electron spin transition coupled at least to a part of the nuclear spin transition of the selected nucleus.
A colonic lipoma is an uncommon lesion that is linked with clinical symptoms in only a small portion of patients. Patients with large lipomas are often referred for major surgery, which is associated with significant morbidity and mortality. In this case, we described a female patient with recurrent episodes of gastrointestinal blood loss, abdominal pain and colocolic intussusceptions due to a large, lumen-filling, obstructive lipoma in the splenic flexure. On abdominal CT, a lesion of 3.6 cm was visualised with a fat-like density without solid components. Considering its benign nature, we intended to preserve the colon by deroofing the upper part of the lesion and then performing a colonoscopy-assisted laparoscopic wedge resection. During reassessment, auto-amputation of part of the lesion was observed, most likely as a result of long-lasting mechanical effects, which made it possible to perform solely a wedge resection with an excellent outcome.
FIELD: medicine, stomatology. SUBSTANCE: invention relates to agents used for mouth cavity care. Curative-prophylactic dental paste has synthetic finely dispersed amorphous silicon dioxide, purified carboxymethylcellulose sodium, distilled glycerol, sorbitol, pigmented titanium dioxide, sodium fluoride, saccharin, sodium lauryl sulfate, aromatic composition, water and, additionally, paste has troclozan, nettle and plantain aqueous-alcohol-glycerol extracts. Components are taken at the definite quantitative ratio. Paste protects teeth from caries and inhibits different inflammatory processes arising in gum tissues. EFFECT: enhanced effectiveness of paste. 1 cl, 2 tbl
PURPOSE:To provide a carcinostatic agent containing a mucous polysaccharide produced by Spirulina subsalsa. CONSTITUTION:The objective carcinostatic agent contains a mucous polysaccharide containing at least rhamnose, fucose, xylose, galactose, glucose, mannose, uronic acid and N-acetylated sugar as the constituent components, and produced by Spirulina subsalsa. The polysaccharide is composed of lambda type spirulinan soluble in an aqueous solution of potassium chloride and kappa type spirulinan insoluble in an aqueous solution of potassium chloride, and has the elemental analysis and ash content shown in the table I. It is administered parenterally in the form of intravenous infusion, intravenous injection, peritoneal infusion, etc. Effective dose for mammals including human is 20-0.01mg/kg daily, preferably 2-0.1mg/kg daily. It can be administered every 1-5 days over a long period.
After the EST and stone extraction, we will randomly assign the patients to either a control or an intervention group. After EST, if immediate bleeding occurs, we will apply standard endoscopic therapy by either local injection of diluted epinephrine or heater probe coagulation. After then, we will spray 1g of sucralfate powder and 0.5g of tranexamic acid powder through a duodenoscope precisely on the EST wound in the intervention group.
This study is evaluating the WIC Fresh Start program, a theory-driven, web-based nutrition education lesson to promote fruit and vegetable (FV) consumption among women enrolled in the Special Supplemental Nutrition Program for Women, Infants and Children (WIC). Designed to leverage vouchers provided to WIC participants for FV purchases through the Farmers' Market Nutrition Program (FMNP) and monthly cash value vouchers (CVVs) redeemable at farmers' markets, the lesson is conceptually grounded in formative research on knowledge, attitudes and skills influencing farmers' market FV purchases and consumption and theoretical understanding of approaches for modifying them. Lesson content delivery is primarily through short video segments and audio output to increase accessibility for low-literate learners. Informed by a community-based participatory research approach, WIC participants are engaged as full partners in the development of the lesson and the delivery of content (videos feature WIC participants). The setting is a large WIC agency serving three New Jersey counties. Separate samples of women were recruited to participate in 1) focus groups for guiding lesson content development (N = 56 participants) and pretesting the resulting content (N = 52 participants), 2) cognitive testing to assess the clarity and interpretability of items and response formats in measures of knowledge, attitudes and skills developed for the study (N = 15), 3) one-on-one sessions to assess reactions to initial versions of video segments developed for the lesson (N = 20), and 4) the outcome evaluation (N = 744). Stratified based on FMNP voucher receipt, participants are randomized to receive the lesson or existing online health education. Outcome measures (administered orally to reduce literacy demands of the response task) are completed at pretest (immediately before the lesson), posttest (two weeks after the lesson), and 3 and 6 months after posttesting. Short- and long-term lesson effects on FV intake, FMNP voucher redemption and the redemption of CVVs at farmers' markets will be evaluated. Evidence for mediation by knowledge, attitudes, and skills of lesson effects on FV intake and voucher redemption, dose-response relationships, and user satisfaction with the lesson also will be examined.
Neuronal voltage-gated KCNQ (Kv7) channels, expressed centrally and peripherally, mediate low-threshold and non-inactivating M-currents responsible for the control of tonic excitability of mammalian neurons. Pharmacological opening of KCNQ channels has been reported to generate analgesic effects in animal models of neuropathic pain. Here, we examined the possible involvement of central KCNQ channels in the analgesic effects of retigabine, a KCNQ channel opener. Behaviorally, intraperitoneally applied retigabine exerted analgesic effects on thermal and mechanical hypersensitivity in male mice developing neuropathic pain after partial sciatic nerve ligation, which was antagonized by the KCNQ channel blocker XE991 preadministered intraperitoneally and intrathecally. Intrathecally applied retigabine also exerted analgesic effects that were inhibited by intrathecally injected XE991. We then explored the synaptic mechanisms underlying the analgesic effects of retigabine in the spinal dorsal horn. Whole-cell recordings were made from dorsal horn neurons in spinal slices with attached dorsal roots from adult male mice developing neuropathic pain, and the effects of retigabine on miniature and afferent-evoked postsynaptic currents were examined. Retigabine reduced the amplitude of A-fiber-mediated EPSCs without affecting C-fiber-mediated excitatory synaptic transmission. A-fiber-mediated EPSCs remained unaltered by retigabine in the presence of XE991, consistently with the behavioral findings. The frequency and amplitude of mEPSCs were not affected by retigabine. Thus, opening of KCNQ channels in the central terminals of primary afferent A-fibers inhibits excitatory synaptic transmission in the spinal dorsal horn, most likely contributing to the analgesic effect of retigabine.
Rationale: Passenger lymphocyte syndrome (PLS) may complicate minor ABO mismatched lung transplantation (LuTX) via donor-derived red cell antibody-induced hemolysis.Objectives: To ascertain the incidence and specificity of PLS-relevant antibodies among the study population as well as the dynamics of hemolysis parameters and the transfusion requirement of patients with or without PLS.Methods: In this cohort study, 1,011 patients who received LuTX between January 2010 and June 2019 were studied retrospectively. Prospectively, 87 LuTX (July 2019 to June 2021) were analyzed. Postoperative ABO antibody and hemolytic marker determinations, transfusion requirement, and duration of postoperative hospital care were analyzed. Retrospectively, blood group A recipients of O grafts with PLS were compared with those without.Measurements and Main Results: PLS affected 18.18% (retrospective) and 30.77% (prospective) of A recipients receiving O grafts, 5.13% of B recipients of O grafts, and 20% of AB patients receiving O transplants. Anti-A and anti-A1 were the predominant PLS-inducing antibodies, followed by anti-B and anti-A,B. Significantly lower hemoglobin values (median, 7.4 vs. 8.3 g/dl; P = 0.0063) and an approximately twice as high percentage of patients requiring blood transfusions were seen in PLS. No significant differences in other laboratory markers, duration of hospital stay, or other complications after LuTX were registered.Conclusions: Minor ABO incompatible LuTX recipients are at considerable risk of developing clinically significant PLS. Post-transplant monitoring combining red cell serology and hemolysis marker determination appears advisable so as not to overlook hemolytic episodes that necessitate antigen-negative transfusion therapy.
Omeprazole delayed-release capsules USP, 10 mg, are hard-shell gelatin capsules with a dark green opaque cap and a dark green opaque body axially printed with MYLAN over 5211 in white ink both on the cap and the body. The capsule is filled with white to off-white beads.

Omeprazole delayed-release capsules USP, 20 mg, are hard-shell gelatin capsules with a dark green opaque cap and a blue-green opaque body axially printed with MYLAN over 6150 in white ink both on the cap and the body. The capsule is filled with white to off-white beads. 

Omeprazole delayed-release capsules USP, 40 mg, are hard-shell gelatin capsules with a dark green opaque cap and a light-blue opaque body axially printed with MYLAN over 5222 in white ink both on the cap and the body. The capsule is filled with white to off-white beads.
Lyophilized lysate of 18 E. coli strains (6 mg) for oral application. A treatment lasts 90 days (one capsule daily).
PROBLEM TO BE SOLVED: To obtain the subject composition producing excellent flatness of the surface in a packaging container and affording an impression of opening a new container each time by including a specific medium thickened with an associating polyurethane. SOLUTION: This composition is such one as to include a physilogically permissible medium thickened with an associating polyurethane wherein this medium comprises an aqueous phase and liquid lipid phase in the form of an emulsion. This composition has at least 5 mg of the associating polyurethane per m2 of the surface area of oil in water, and the polyurethane content is pref. 2-20 wt.%, based on the total weight of the composition. The associating polyurethane is a triblock polymer or the like. The aqueos phase can include a medium containing especially, e.g. a polyol. As the liquid lipid phase, vegetable oil, animal oil, hydrocarbon, silicone or the like is pref. used. This composition can be used for makeup, treatment and the like.